Resonance Health Ltd (AU:RHT) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Resonance Health Ltd, listed on the ASX, is making waves in the healthcare technology sector with its Software-as-a-Medical Device (SaMD) and clinical trial services, utilized in over 400 locations globally. The company’s strategic acquisition of TrialsWest in June 2024 has further strengthened its position, partnering with top pharmaceutical and biotech firms. This expansion highlights Resonance Health’s growing influence in the clinical research and medical imaging markets.
For further insights into AU:RHT stock, check out TipRanks’ Stock Analysis page.